Our Research

At Skin Analytics research is at the very core of everything that we do. 

Observational Study

We’ve undertaken a study on over 6,000 biopsy confirmed mole images.

The results of this study confirmed that our AI, Deep Ensemble for the Recognition of Malignancy (DERM), is as accurate as a dermatologist. We have the results and are publishing the paper soon. Watch this space.

Pioneering Research

We’ve conducted the world’s first prospective study for AI and melanoma.

We’re just finished the world’s first clinical trial for AI melanoma detection across 7 NHS hospitals, led by the Royal Free London.

The study was designed by leading clinicians to ensure that results truly represent the efficacy of our solution. We look forward to be able to share those results with you in early 2019.

Non-melanoma Skin Cancer

With a grant run by the Small Business Research Initiative (SBRI) and funded by the NHS we expanded our focus from melanoma to include non-melanoma skin cancer as well. This research produced stunning results and we’ll follow this up with a research paper with one of our partners soon.

Non-melanoma skin cancers are less dangerous than melanoma, but they are also far more common. The diagnosis and treatment of non melanoma skin cancer places a significant burden on the health care system.

Health Economics

We partnered with Advance Queensland under an Ignite Grant and are conducting a study into the health economic benefits of using DERM to help detect skin cancer in primary care.

With the help of leading researchers at Griffith University we have designed a study to work alongside GP’s to help establish how the use of DERM would affect the rate of biopsies conducted.  We plan to show that the use of AI in primary care can reduce the number of biopsies needed to find skin cancer.

We would like to thank Ignite Queensland, Griffith University and Pioneer Health for their support with our research.

Get in Touch

  • This field is for validation purposes and should be left unchanged.